ESG

New data on MCO-010 gene therapy identifies ideal patients for Retinitis Pigmentosa, a key step as the one-time injection advances toward FDA approval.

With pivotal data imminent for its blockbuster hopeful AXPAXLI, Ocular Therapeutix faces a critical month of investor meetings amid commercial headwinds.

Maiden drilling at West Santa Fe reveals significant near-surface gold, sparking speculation of a low-cost, open-pit mine in the prolific Walker Lane.

Swiss biotech AC Immune begins a human trial for an oral drug aiming to halt the chronic inflammation driving diseases like Alzheimer's and Parkinson's.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

A new report shows patients are rejecting 'overdone' looks for subtle, strategic care, driven by Ozempic, menopause, and a desire for authenticity.

New Phase 1b data for oral drug pociredir reveals a robust boost in fetal hemoglobin, as Fulcrum Therapeutics secures a financial runway into 2029.

The M&M's maker's new renewable energy contract in Sweden is a blueprint for corporate decarbonization, powering its supply chain and local communities.

Singapore's OUE REIT makes a strategic A$357M entry into Australia, acquiring a stake in Sydney's prime, green-certified Salesforce Tower.

US consumers are sitting on $83B in unused tech. New research shows why brands failing to offer good trade-in programs are losing revenue and loyalty.

Storage Post acquires its seventh Long Island location, a Plainview facility featuring a geothermal system, signaling a strategic push into sustainable self-storage.

After an 8-year hiatus, Elizabeth Arden launches Eternal Aura. A look at the strategy combining a new star, wellness science, and heritage to reclaim its spot.

The former South Pole CEO's appointment signals a new era for PUR, focusing on high-integrity carbon markets and scaling holistic climate solutions.

Avacta's pre|CISION therapy shows faster, more potent, and more selective tumor targeting than Enhertu in an AI-driven study, paving the way for 2026 trials.

Urban Armor Gear's sustainability award places it in the top 13% globally. What does this mean for the future of rugged, eco-conscious tech accessories?

The fusion energy pioneer plans to go public via a SPAC merger, seeking capital to prove its unique technology and win the race for limitless clean power.

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

A former hedge fund manager's stark video presentation warns that AI will permanently alter work and wealth. Are American workers prepared for what's next?

With a new CEO and a key investor conference ahead, Metagenomi bets on its unique metagenomics platform and a hemophilia drug to navigate a tough market.